Viewpoint: The Brazilian HIV/AIDS ‘success story’– can others do it?

Discussions on the use of anti-retroviral drugs (ARVs) in developing countries have in the past focused on the limitations caused by the high cost of the drugs and by the lack of health system capacity to adequately deliver and make use of them (Colebunders et al. 2000; The New York Times 2001). An additional concern has been the risk of increasing resistance to ARVs if there were widespread inappropriate administration and lack of monitoring (Harries et al. 2001). Lately, however, including at the 2002 International AIDS Conference in Barcelona, there have been stronger calls for scaling up access to ARVs with less attention paid to these concerns and limitations, as expressed by Lange (2002): ‘If we can get cold Coca-Cola…